Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Gsk (GLAXF) over the last 17 years, with Q4 2025 value amounting to $3.6 billion.

  • Gsk's Cash from Operations rose 37.78% to $3.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $11.9 billion, marking a year-over-year increase of 2898.9%. This contributed to the annual value of $11.8 billion for FY2025, which is 1736.47% up from last year.
  • Per Gsk's latest filing, its Cash from Operations stood at $3.6 billion for Q4 2025, which was up 37.78% from $3.4 billion recorded in Q3 2025.
  • Gsk's 5-year Cash from Operations high stood at $3.7 billion for Q1 2022, and its period low was $348.9 million during Q1 2023.
  • For the 5-year period, Gsk's Cash from Operations averaged around $2.3 billion, with its median value being $2.3 billion (2021).
  • Its Cash from Operations has fluctuated over the past 5 years, first skyrocketed by 45162.68% in 2022, then tumbled by 9056.33% in 2023.
  • Over the past 5 years, Gsk's Cash from Operations (Quarter) stood at $2.2 billion in 2021, then soared by 31.13% to $2.9 billion in 2022, then decreased by 17.5% to $2.4 billion in 2023, then soared by 50.54% to $3.6 billion in 2024, then rose by 0.38% to $3.6 billion in 2025.
  • Its Cash from Operations was $3.6 billion in Q4 2025, compared to $3.4 billion in Q3 2025 and $3.2 billion in Q2 2025.